Analysis of Potential Antidiabetic Drug Interactions in Patients with Type 2 Diabetes Mellitus Hospitalized at Bandar Lampung X Hospital
DOI:
https://doi.org/10.35451/jfm.v9i1.3908Keywords:
Type 2 diabetes mellitus, drug interaction, antidiabetic drugs, Hospitalized PatientsAbstract
Background: Diabetes mellitus is a chronic metabolic disease characterized by hyperglycemia. Hospitalized patients with type 2 diabetes mellitus commonly have comorbidities requiring the concomitant use of multiple medications, which increases the risk of drug interactions that may affect therapeutic effectiveness and increase adverse effects. Objective: This study aimed to determine the potential drug interactions of antidiabetic medications among hospitalized patients with type 2 diabetes mellitus at Hospital X Bandar Lampung in 2025. Methods: This study used a non-experimental method with a retrospective descriptive design. Data were obtained from medical records for the period of January–August 2025. The study population consisted of 612 patients, with a sample of 242 patients selected using systematic random sampling. Potential drug interactions were identified using Medscape and Drugs.com. Results and Discussion: The results show that 169 patients (69.8%) have potential drug interactions, while 73 patients (30.2%) have no potential interactions. A total of 428 potential drug interaction events are identified, consisting of 351 pharmacodynamic interactions (82%) and 77 pharmacokinetic interactions (18%). Based on severity, moderate interactions account for 334 events (78%), while minor interactions account for 94 events (22%). The most frequently identified interaction is between aspirin and insulin glargine, with 20 events (4.7%). Conclusion: This study shows that the potential for drug interactions among hospitalized patients with type 2 diabetes mellitus remains considerable, indicating the need for medication therapy monitoring to improve the safety and effectiveness of treatment.
Downloads
References
[1] Perkumpulan Endokrinologi Indonesia. Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2024. Pengurus Besar Perkumpulan Endokrinologi Indonesia, 2024.
[2] Suryanti, Asmanidar, Manalu TA, Azhar B, Sumara R, Fadli. Diabetes Mellitus Dan Pencegahan Komplikasi. Jakarta: Nuansa Fajar Cemerlang, 2025.
[3] Kementerian Kesehatan Republik Indonesia. Survei Kesehatan Republik Indonesia Tahun 2023. Jakarta: Kementerian Kesehatan Republik Indonesia, 2023.
[4] Lasmawati E, Putri DF, Nuryani DD. Analisis Faktor yang Berhubungan dengan Kejadian Diabetes Melitus Tipe 2. Holistik Jurnal Kesehatan. 2023);17(4), 334–344.
[5] Fitriani A, Padmasari S. Analisis Potensi Interaksi Obat Antidiabetik pada Pasien Diabetes Melitus Tipe 2 Rawat Inap RS PKU Muhammadiyah Gamping Yogyakarta. Majalah Farmaseutik. 2022;18(1), 37–42
[6] Indrawan SA, Yulianti T. Identifikasi Drug Related Problems (DRPs) Pada Pasien Diabetes Mellitus Di Instalasi Rawat Jalan. Usadha: Journal of Pharmacy, 2024;3(1), 29–42.
[7] Rahayu FP, Susilawati Y. Identifikasi Interaksi Obat pada Resep Tentang Gangguan Pernapasan di Bulan Februari 2023 di Apotek Kota Bandung. Farmaka. 2023;21(3), 298–306.
[8] Leny Nopitasari B. Evaluasi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan di Rumah Sakit Umum Daerah Provinsi NTB Tahun 2021. Jurnal Ilmu Kefarmasian. 2023;4(1), 186–190.
[9] Ariani N, Prihandiwati E. Evaluasi Potensi Interaksi Obat Antidiabetika Oral di Apotek Perintis Kuripan Banjarmasin. Jurnal Insan Farmasi Indonesia. 2021;4(2), 302–308.
[10] Shrestha P, Sah AK, Alam K, Sarraf DP, Mallik SK. Prescription Audit and Drug Interactions of Anti-diabetic Drugs at Outpatient Department at a Tertiary Care Teaching Hospital in Eastern Nepal. Nepal Medical College Journal. 2023;25(3), 223–229.
[11] Nurhasanah R, Harahap U. Potential Drug Interactions of Oral Antidiabetic in Prescriptions of Type 2 Diabetes Mellitus Patients at Kumpulan Pane Hospital. International Journal of Science,Technology & Management. 2020:1378–1382.
[12] Khomisah I, Fatoni R. Gambaran Penggunaan Obat Antidiabetes Pasien Diabetes Melitus Tipe 2 dI Instalasi Rawat Inap RSUD Kajen Kabupaten Pekalongan Periode Januari-Juli 2023. Jurnal Farmasi, Sains, dan Kesehatan. 2024;3(2),112-122.
[13] Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Diabetes Melitus Tipe 2 Dewasa. Kementerian Kesehatan Republik Indonesia, 2020.
[14] Zahara A, Efmisa A, Armal K, Jannah M. Analisis Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Ruang Rawat Inap RS Islam Ibnu Sina Bukittinggi Periode September 2023-Agustus 2024. Journal of Science and Clinical Pharmacy Research (JSCPR). 2025;1(2), 75-91.
[15] Zulfa F, Mutmainah N. Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 dengan Komplikasi di Instalasi Rawat Inap Rumah Sakit. Usadha: Journal of Pharmacy, 2025;4(3), 238-248.
[16] Musawe A, Torre C, Guerreiro JP, Rodrigues AT, Raposo JF, Filipe HM, Martins AP. Polypharmacy, Potentially Serious Clinically Relevant Drug-Druginteractions, And Inappropriate Medicines in Elderly Peoplewith Type 2 Diabetes and Their Impact on Quality of Life. Pharmacol Res Perspect. 2020:1-9.
[17] Pradifta R, Alifiar I, Fatwa M. Kajian Interaksi Obat Antidiabetik dengan Obat Lain pada Pasien Diabetes Mellitus Rawat Inap di RSUD dr. Soekardjo Tasikmalaya. Journal of Pharmacopolium. 2019;2(2), 88-93.
[18] Rasdianah N, Madania M, Pakaya M. Studi Interaksi Obat Pasien Diabetes Melitus Tipe 2 dengan Penyakit Penyerta: Studi Kasus Rumah Sakit X Gorontalo. Journal Syifa Sciences and Clinical Research. 2023;5(1), 192–199.
[19] Zarak MS, Khalafalla S, Batta Y, Mere C, Mehari A. Hemodialysis as an Effective Treatment for Combined Amlodipine and Metformin Overdose: A Case Report and Literature Review. Cureus. 2023;15(6), 1-7.
[20] Medscape Drug Reference. Drug Interaction Checker [Internet]. 2026 [cited 2026 Jun 3]. Available from: https://www.medscape.com/pharmacists.
[21] Drugs.com. Drug Interaction Checker [Internet]. 2026 [cited 2026 Jun 3]. Available from: https://www.drugs.com/drug_interactions.html.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Putu Rara Tretilia, Annisa Primadiamanti, Nova Muhani
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
